자발적인 헌혈의 증가는 수혈을 위한 혈액형 인식 및 크로스 매칭 절차에 대한 보다 높은 수요로 이어지고 있습니다. 따라서 자발적인 헌혈의 증가는 2024년에 29억 6,000만 달러를 돌파하며, 2031년까지 61억 6,000만 달러의 평가에 도달하는 시장 규모의 성장을 급증시켰습니다.
암, 혈액 질환, 만성 빈혈과 같은 질병의 발생률이 증가함에 따라 수혈의 필요성과 혈액형 검사의 필요성이 증가하고 있습니다. 따라서 수혈이 필요한 만성질환의 유병률 증가로 인해 시장은 2024-2031년 연평균 복합 성장률(CAGR) 9.60%로 성장할 것으로 예상됩니다.
혈액형타이핑 시장 정의/개요
혈액형 검사는 적혈구 표면의 특정 항원을 식별하여 사람의 혈액형을 결정하는 중요한 의료 절차입니다. 이 과정은 수혈 및 장기 이식의 적합성을 보장하고, 산모의 면역 체계가 태아의 적혈구를 공격하여 발생하는 신생아 용혈성 질환을 예방하기 위해 임신을 관리하는 등 다양한 의료적 용도에 매우 중요합니다.
정확한 혈액형 검사에 대한 수요는 수혈과 장기 이식의 필요성이 증가함에 따라 지속적으로 증가하고 있습니다. 세계보건기구(WHO)의 보고에 따르면 2008-2018년 1,070만 건의 헌혈이 증가하여 자발적 헌혈이 크게 증가했으며, 이에 따라 혈액형 검사도 증가하고 있습니다. 이러한 수요 증가는 전 세계에서 사고, 외상 및 부상 건수가 증가함에 따라 더욱 가속화되고 있습니다. 조사에 따르면 외상 관련 사망 10건 중 6건이 처음 3시간 이내에 다량의 출혈로 인한 것으로 나타나 정확한 혈액형 검사가 필요한 적시 수혈의 중요성이 강조되고 있습니다.
유전자 검사와 분자진단의 발전으로 혈액형 검사의 정확성과 속도가 향상되어 보다 정확하고 맞춤화된 헬스케어 솔루션의 길을 열어가고 있습니다. 의료 시스템이 환자의 안전과 맞춤 치료를 우선시함에 따라 신뢰할 수 있는 혈액형 검사에 대한 수요가 증가하고 의료 및 헬스케어에 대한 적용이 더욱 확대될 것으로 예상됩니다.
분자 타이핑 및 자동화 시스템과 같은 혈액형 검사 기술의 혁신은 혈액형 검사의 효율성과 정확성을 높이고 있으며, 2020년 Transfusion Medicine Reviews 저널에 게재된 연구에 따르면 혈액 은행의 자동 혈액형 검사 시스템 채택은 2015-2019년까지 2019년 사이에 35% 증가했습니다. 정확한 혈액형 분류의 중요성에 대한 의료진과 환자들의 인식이 높아지면서 시장 성장의 원동력이 되고 있습니다. 미국 의료기관 인증기관인 Joint Commission은 2018년 강력한 수혈 전 검사를 포함한 환자 혈액 관리 프로그램 시행으로 참여 병원의 혈액제제 사용량이 평균 12% 감소했다고 보고했습니다.
수혈이 필요한 수술 건수가 증가하면서 혈액형 검사에 대한 수요가 증가하고 있습니다. 미국 질병예방통제센터(CDC)의 보고에 따르면 2018년 미국 병원에서 4,830만 건의 외과 및 비외과수술이 이루어졌으며, 이 중 상당수는 혈액형 검사가 필요하고 수혈이 필요할 수 있습니다. National Vital Statistics Reports에 따르면 2019년 미국에서는 약 3,750만 건의 출산이 있을 것으로 예상되며, 산모와 태아 간 혈액형 검사 등 산전 및 신생아 관리에 대한 관심이 높아지면서 시장 성장의 원동력이 될 것으로 보입니다. 혈액형 검사가 필요할 수 있습니다.
특히 신흥 국가에서는 혈액형 검사 인프라의 미비한 인프라가 큰 걸림돌로 작용하고 있습니다.2019년 세계보건기구(WHO) 보고서에 따르면 국가 혈액정책이 있는 국가는 62%에 불과했고, 중저소득 국가는 48%로 가장 낮았습니다. 최신 혈액형 검사 장비와 시약은 고가이기 때문에 특히 자원이 부족한 환경에서는 도입이 제한되며, 2018년 Transfusion Medicine 저널에 게재된 연구에 따르면 중형 혈액은행에 완전 자동 혈액형 검사 시스템을 도입하는 데 드는 비용은 10만 달러에서 50만 달러에 달하는 것으로 추정됩니다. 으로 추정되어 보급이 제한적일 수 있습니다.
고급 혈액형 검사 시스템을 운영할 수 있는 숙련된 인력이 부족하여 시장 성장을 저해하고 있습니다. 미국 임상병리학회(American Society of Clinical Pathology)의 2018년 결원 조사에 따르면 미국 혈액은행 기술자/전문가의 결원율은 10.6%로 이 분야의 숙련된 전문가가 크게 부족한 것으로 나타났습니다. 수작업 방식은 특히 자원이 제한된 환경에서 여전히 널리 사용되고 있지만, 인위적인 실수가 발생하기 쉽기 때문에 신뢰와 채택을 제한할 수 있습니다. 학술지 Transfusion에 게재된 2020년 메타분석에 따르면 수작업 혈액 타이핑의 오류율은 특정 기술과 환경에 따라 0.05%에서 0.8% 사이로 나타났습니다.
The increase in voluntary blood donations has led to a higher demand for blood group recognition and cross-matching procedures for transfusion. Thus, the increase in voluntary blood donations surged the growth of market size surpassing USD 2.96 Billion in 2024 to reach the valuation of USD 6.16 Billion by 2031.
The increasing incidence of diseases like cancer, blood disorders, and chronic anemia is driving the need for blood transfusions and, consequently, blood typing. Thus, the rising prevalence of chronic diseases requiring blood transfusions enables the market to grow at aCAGR of 9.60% from 2024 to 2031.
Blood Group Typing Market: Definition/ Overview
Blood group typing is a vital medical procedure that determines a person's blood type by identifying specific antigens on the surface of red blood cells. This process is crucial in various medical applications, such as ensuring compatibility for blood transfusions and organ transplants, as well as managing pregnancies, to prevent hemolytic disease of the newborn, which occurs when the mother's immune system attacks the fetus's red blood cells.
The demand for accurate blood group typing continues to grow, driven by the increasing need for blood transfusions and organ transplantations. The World Health Organization (WHO) reports a significant rise in voluntary blood donations, with an increase of 10.7 million donations between 2008 and 2018, indicating a corresponding rise in blood typing procedures. This rise in demand is further fueled by the growing number of accidents, trauma, and injury cases worldwide. Research indicates that 6 out of 10 trauma-related deaths result from excessive bleeding within the first three hours, underscoring the importance of timely blood transfusions, which require accurate blood group typing.
Advancements in genetic testing and molecular diagnostics are enhancing the accuracy and speed of blood typing procedures, paving the way for more precise and tailored healthcare solutions. As healthcare systems prioritize patient safety and personalized treatment, the demand for reliable blood group typing is expected to rise, further expanding its medical and healthcare applications.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Innovations in blood typing technologies, such as molecular typing and automated systems, are enhancing the efficiency and accuracy of blood group typing. A 2020 study published in the journal Transfusion Medicine Reviews found that the adoption of automated blood typing systems in blood banks increased by 35% between 2015 and 2019. Increased awareness among healthcare providers and patients about the critical nature of accurate blood typing is driving market growth. The Joint Commission, which accredits healthcare organizations in the U.S., reported in 2018 that the implementation of patient blood management programs, which include robust pre-transfusion testing, reduced blood product utilization by an average of 12% in participating hospitals.
The rising number of surgical procedures, many of which require blood transfusions, is boosting the demand for blood group typing. The Centers for Disease Control and Prevention (CDC) reported that in 2018, there were 48.3 million surgical and nonsurgical procedures performed in U.S. hospitals, with many requiring blood typing and potential transfusions. The growing focus on prenatal and neonatal care, including blood type compatibility testing between mother and fetus, is driving market growth. According to the National Vital Statistics Reports, there were approximately 3.75 million births in the United States in 2019, each potentially requiring blood typing for both mother and child.
The lack of infrastructure for blood group typing, especially in emerging countries, is a significant restraint. According to a 2019 World Health Organization report, only 62% of countries had national blood policies, with lower-middle-income countries having the lowest rate at 48%. The expensive nature of modern blood typing equipment and reagents limits adoption, especially in resource-constrained settings. A 2018 study published in the journal Transfusion Medicine estimated that the cost of implementing a fully automated blood typing system in a medium-sized blood bank could range from $100,000 to $500,000, potentially limiting widespread adoption.
The lack of trained personnel to operate advanced blood typing systems hinders market growth. The American Society for Clinical Pathology's 2018 Vacancy Survey reported a vacancy rate of 10.6% for blood bank technologists/specialists in the United States, indicating a significant shortage of skilled professionals in the field. While manual methods are still widely used, especially in resource-limited settings, they are prone to human error, which can limit trust and adoption. A 2020 meta-analysis published in the journal Transfusion found that the error rate in manual blood typing ranged from 0.05% to 0.8%, depending on the specific technique and setting.
The ABO segment is dominant in the blood group testing market, driven by the rising prevalence of chronic diseases and the increasing number of surgical procedures requiring blood transfusions. Accurate ABO blood typing is crucial in ensuring compatibility between blood donors and recipients, significantly reducing the risk of adverse reactions during medical procedures. As a result, there has been a notable surge in demand for ABO blood typing tests, which is propelling the growth of this market segment.
Moreover, advancements in medical technology and diagnostic instruments have significantly enhanced the accuracy and efficiency of blood typing systems. The ability to swiftly and accurately determine blood types through automated methods has heightened the demand for ABO blood typing tests. Healthcare professionals prioritize patient safety and the reliability of medical procedures, making ABO testing an indispensable tool in modern healthcare. This growing emphasis on precision and efficiency ensures that the ABO segment will continue to dominate the blood group testing market in the years to come.
The reagents & kits segment holds a dominant position in the blood group testing market, driven by their extensive use in blood donation and transfusion procedures. These products are essential for accurate blood typing, making them a critical component in ensuring compatibility between donors and recipients, particularly in life-saving situations such as surgeries, trauma care, and organ transplants. As the global demand for blood donations and transfusions continues to rise, the use of reagents & kits in healthcare facilities and blood banks has significantly increased, fueling the segment's growth.
The surge in voluntary blood donations and the expansion of healthcare infrastructure worldwide. With more individuals donating blood, the demand for reliable and efficient blood typing reagents has become paramount. Additionally, reagents are indispensable in determining blood types quickly and accurately, ensuring patient safety during transfusion procedures.
In addition, the segment is poised for continued growth as the adoption of advanced diagnostic technologies accelerates. As healthcare systems increasingly rely on automated and high-throughput instruments for blood typing, the need for specialized reagents & kits to complement these systems is expected to rise, ensuring the segment's strong presence in the market throughout the forecast period.
North America substantially dominates the blood group testing market owing to the high demand for blood transfusions in North America, particularly in the United States. According to the American Red Cross, approximately 29,000 units of red blood cells are needed every day in the U.S. The organization also reports that nearly 16 million blood components are transfused each year in the United States.
The increased adoption of automated blood typing systems in North American healthcare facilities is driving market growth. A 2019 survey by the College of American Pathologists reported that 78% of participating laboratories in the U.S. and Canada were using fully or partially automated systems for ABO/Rh typing, up from 65% in 2014.
The favorable reimbursement policies for blood typing procedures and the rising number of regulatory approvals for advanced products are driving market growth in North America. The Centers for Medicare & Medicaid Services (CMS) reported that in 2020, the national average Medicare reimbursement for ABO and Rh blood typing (CPT code 86900) was $7.77, while for antibody screening (CPT code 86850) it was $17.28, providing financial incentives for healthcare providers to perform these tests. Additionally, the U.S. Food and Drug Administration (FDA) approved 12 new or updated blood typing-related products between 2018 and 2020, indicating a growing market for advanced blood typing technologies.
Asia Pacific is anticipated to witness the fastest growth in the blood group testing market driven by the prevalence of chronic diseases like cancer and kidney disorders is growing in Asia Pacific countries, leading to a higher demand for blood transfusions and typing. According to the World Health Organization (WHO), the number of new cancer cases in the Asia-Pacific region is expected to increase from 8.8 million in 2018 to 11.5 million by 2025. This 30% increase will likely drive up the need for blood typing and transfusions.
Many Asia Pacific countries are investing heavily in healthcare infrastructure and increasing their healthcare spending, which supports the expansion of blood typing services. The Indian government's healthcare expenditure increased from 1.2% of GDP in 2013-14 to 1.8% in 2020-21, according to the Economic Survey 2020-21. This growth in healthcare spending is likely to boost investments in blood typing technologies and services.
There's an increasing awareness about the importance of blood donation in the region, supported by various government and non-government initiatives. In China, the number of voluntary blood donors increased from 12.32 million in 2011 to 15.48 million in 2019, according to data from the National Health Commission of China. This 25% increase in blood donors over eight years indicates a growing need for efficient blood typing services.
The Blood Group Testing Market is a dynamic and competitive industry driven by factors such as increasing healthcare expenditure, growing awareness of blood group compatibility, and advancements in testing technologies. Several key players operate in this market, offering a range of products and services to meet the diverse needs of healthcare providers, blood banks, and individual consumers.
The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the blood group typing market include: